How does CURAS's PB Ratio compare to its peers?

CURAS is expensive based on its Price-To-Book Ratio (16.9x) compared to the peer average (7.3x).

How does CURAS's PB Ratio compare vs other companies in the SE Biotechs Industry?

CURAS is expensive based on its Price-To-Book Ratio (16.9x) compared to the Swedish Biotechs industry average (2.4x).

What is CURAS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate CURAS's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of CURAS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate CURAS's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Curasight (NGM:CURAS) - Stock Price, News & Analysis

CURAS Stock Overview

A biotech company, develops treatment of cancer. More details

CURAS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Revenue is forecast to grow 105.6% per year

Risk Analysis

Earnings have declined by 44.9% per year over past 5 years

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (DKK0)

Volatile share price over the past 3 months compared to the Swedish market

+ 2 more risks

Curasight A/S Competitors

Lipum

OM:LIPUM

SEK 354.2m

Initiator Pharma

OM:INIT

SEK 362.8m

Cantargia

OM:CANTA

SEK 332.8m

Alzinova

OM:ALZ

SEK 331.7m

Price History & Performance

Summary of all time highs, changes and price drops for Curasight
Historical stock prices
Current Share Price	DKK 10.90
52 Week High	DKK 19.90
52 Week Low	DKK 8.16
Beta	0.057
11 Month Change	-2.24%
3 Month Change	-5.22%
1 Year Change	-39.28%
33 Year Change	-62.41%
5 Year Change	n/a
Change since IPO	-46.31%

Curasight (NGM:CURAS) Is Making Moderate Use Of Debt

Aug 29

Recent updates

Curasight (NGM:CURAS) Is Making Moderate Use Of Debt

Aug 29

Shareholder Returns

	CURAS	SE Biotechs	SE Market
7D	-4.8%	-0.5%	-0.2%
1Y	-39.3%	14.3%	11.8%

Return vs Industry: CURAS underperformed the Swedish Biotechs industry which returned 14.3% over the past year.

Return vs Market: CURAS underperformed the Swedish Market which returned 11.8% over the past year.

Price Volatility

Is CURAS's price volatile compared to industry and market?
CURAS volatility
CURAS Average Weekly Movement	11.1%
Biotechs Industry Average Movement	9.3%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

Stable Share Price: CURAS's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: CURAS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

Founded	Employees	CEO	Website
2013	4	Ulrich Krasilnikoff	www.curasight.com

Curasight A/S, a biotech company, develops treatment of cancer. The company exploits a novel Positron Emissions Tomography (PET) imaging platform that targets the urokinase-type plasminogen activator receptor (uPAR). It develops uTRACE for enhanced evaluation of cancer disease across several cancer types has been confirmed in multiple phase II clinical trials; and uTREAT, a uPAR targeted radionuclide therapy is using uTRACE together with radiation therapy to irradiate cancer with limited irradiation of healthy tissue.

Curasight A/S Fundamentals Summary

How do Curasight's earnings and revenue compare to its market cap?
CURAS fundamental statistics
Market cap	DKK 225.44m
Earnings (TTM)	-DKK 32.29m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-7.0x

P/E Ratio

Is CURAS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CURAS income statement (TTM)
Revenue	DKK 0
Cost of Revenue	DKK 28.01m
Gross Profit	-DKK 28.01m
Other Expenses	DKK 4.28m
Earnings	-DKK 32.29m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.56
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	78.2%

How did CURAS perform over the long term?

See historical performance and comparison

CURAS Stock Overview

Rewards

Risk Analysis

Curasight A/S Competitors

OM:LIPUM

SEK 354.2m

OM:INIT

SEK 362.8m

OM:CANTA

SEK 332.8m

OM:ALZ

SEK 331.7m

Price History & Performance

Recent News & Updates

Curasight A/S Announces Clinical Supply Agreement with Curium for uTREAT® Development and Commercialization

Curasight A/S Announces International Patent Application for uTREAT® to Broaden IP Protection

Curasight A/S Publishes Clinical Phase II Trial of uPAR-PET in Brain Cancer Patients; Data Supports Development of uTREAT for Brain Cancer

New major risk - Financial position

Curasight A/S to Report Q3, 2024 Results on Nov 21, 2024

Curasight (NGM:CURAS) Is Making Moderate Use Of Debt

Recent updates

Curasight A/S Announces Clinical Supply Agreement with Curium for uTREAT® Development and Commercialization

Curasight A/S Announces International Patent Application for uTREAT® to Broaden IP Protection

Curasight A/S Publishes Clinical Phase II Trial of uPAR-PET in Brain Cancer Patients; Data Supports Development of uTREAT for Brain Cancer

New major risk - Financial position

Curasight A/S to Report Q3, 2024 Results on Nov 21, 2024

Curasight (NGM:CURAS) Is Making Moderate Use Of Debt

New minor risk - Shareholder dilution

Curasight A/S to Report Q2, 2024 Results on Aug 22, 2024

Curasight A/S to Report Q3, 2024 Results on Jul 02, 2024

New major risk - Share price stability

New major risk - Financial position

Curasight A/S to Report Q1, 2024 Results on May 23, 2024

Less than half of directors are independent

Curasight A/S Announces Approval of Clinical Trial Application (CTA) for Phase 2 Trial with uTRACE in Prostate Cancer Patients

Curasight A/S Announces Board Changes

Curasight A/S has withdrawn its Follow-on Equity Offering in the amount of SEK 51.155712 million.

Curasight A/S, Annual General Meeting, Mar 21, 2024

Curasight A/S has filed a Follow-on Equity Offering in the amount of SEK 51.155712 million.

Curasight A/S to Report Fiscal Year 2023 Results on Feb 22, 2024

Curasight Gears Up for Phase II Study in Prostate Cancer

Curasight A/S to Report Q3, 2023 Results on Nov 24, 2023

New minor risk - Share price stability

Curasight A/S Reports Positive Preclinical Results with uTREAT[®] in lung cancer (NSCLC)

Curasight A/S Announces Positive Results from the Phase II Study of uTRACE in Brain Cancer Presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

Curasight A/S to Report Q2, 2023 Results on Aug 24, 2023

Curasight A/S Announces Positive Results in Upar-Pet/MR Phase II Study in Brain Cancer

Curasight A/S Reports Positive Preclinical Results with uTREAT in Aggressive Brain Cancer (Glioblastoma)

Curasight A/S to Report Fiscal Year 2022 Results on Feb 23, 2023

Curasight A/S Initiates Pre-Clinical Studies with uTREAT Therapy in Head and Neck Cancer and Neuroendocrine Tumors

Curasight A/S Announces Recruitment Completes in uPAR-PET Study in Brain Cancer

Curasight A/S, Annual General Meeting, Mar 24, 2022

Curasight A/S Announces Positive Data of uTREAT® in Glioblastoma Provides "Green Light" to Proceed with Next Steps

New 90-day high: kr.41.50

New 90-day high: kr.34.45

Curasight Announces Results from Phase II Study in Prostate Cancer to Be Published in the Journal of Nuclear Medicine

Curasight A/S to Report Q1, 2021 Results on May 20, 2021

Curasight A/S Initiates Pre-Clinical Study on Therapy in Brain Cancer and Signs CRO-Agreement

Curasight A/S has completed an IPO in the amount of DKK 32.688 million.

Shareholder Returns

Price Volatility

About the Company

Curasight A/S Fundamentals Summary

0.0x

-7.0x

Earnings & Revenue